UA115781C2 - Cx3cr1-зв'язуючий поліпептид - Google Patents

Cx3cr1-зв'язуючий поліпептид

Info

Publication number
UA115781C2
UA115781C2 UAA201410430A UAA201410430A UA115781C2 UA 115781 C2 UA115781 C2 UA 115781C2 UA A201410430 A UAA201410430 A UA A201410430A UA A201410430 A UAA201410430 A UA A201410430A UA 115781 C2 UA115781 C2 UA 115781C2
Authority
UA
Ukraine
Prior art keywords
polypeptide
cx3cr1
variable domain
specified
single variable
Prior art date
Application number
UAA201410430A
Other languages
English (en)
Ukrainian (uk)
Inventor
Санджая Сінгх
Аліса К. Ватерман
Ерік Депла
Тон Лареманс
Хорік Діане ван
Седрік Жозеф Неотер Верверкен
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115781(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA115781C2 publication Critical patent/UA115781C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
UAA201410430A 2012-02-27 2013-02-25 Cx3cr1-зв'язуючий поліпептид UA115781C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603622P 2012-02-27 2012-02-27
PCT/US2013/027580 WO2013130381A1 (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides

Publications (1)

Publication Number Publication Date
UA115781C2 true UA115781C2 (uk) 2017-12-26

Family

ID=47884535

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201410430A UA115781C2 (uk) 2012-02-27 2013-02-25 Cx3cr1-зв'язуючий поліпептид

Country Status (27)

Country Link
US (6) US9035029B2 (cg-RX-API-DMAC10.html)
EP (2) EP4050027A3 (cg-RX-API-DMAC10.html)
JP (1) JP6101715B2 (cg-RX-API-DMAC10.html)
KR (1) KR102008136B1 (cg-RX-API-DMAC10.html)
CN (3) CN108610421B (cg-RX-API-DMAC10.html)
AP (1) AP2014007791A0 (cg-RX-API-DMAC10.html)
AR (1) AR090158A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013226340B2 (cg-RX-API-DMAC10.html)
CA (1) CA2862182A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014002072A1 (cg-RX-API-DMAC10.html)
EA (1) EA028183B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14020402A (cg-RX-API-DMAC10.html)
GE (1) GEP201706773B (cg-RX-API-DMAC10.html)
IL (3) IL291571B2 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN05756A (cg-RX-API-DMAC10.html)
MD (1) MD4548C1 (cg-RX-API-DMAC10.html)
MX (1) MX349192B (cg-RX-API-DMAC10.html)
NZ (1) NZ627260A (cg-RX-API-DMAC10.html)
PE (1) PE20141859A1 (cg-RX-API-DMAC10.html)
PH (2) PH12014501912B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201405283SA (cg-RX-API-DMAC10.html)
TN (1) TN2014000360A1 (cg-RX-API-DMAC10.html)
TW (1) TWI598361B (cg-RX-API-DMAC10.html)
UA (1) UA115781C2 (cg-RX-API-DMAC10.html)
UY (1) UY34644A (cg-RX-API-DMAC10.html)
WO (1) WO2013130381A1 (cg-RX-API-DMAC10.html)
ZA (3) ZA201405021B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
NZ627260A (en) 2012-02-27 2015-10-30 Boehringer Ingelheim Int Cx3cr1-binding polypeptides
EP3035970A1 (en) * 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
SG10201913807QA (en) 2015-07-23 2020-03-30 Inhibrx Inc Multivalent and multispecific gitr-binding fusion proteins
CN108883153A (zh) * 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
TW202302631A (zh) * 2016-03-08 2023-01-16 日商武田藥品工業股份有限公司 可誘導性結合蛋白和使用方法
CN109963593B (zh) * 2016-11-29 2023-02-28 国立研究开发法人国立精神·神经医疗研究中心 进展型免疫性脱髓鞘病的预防、发病抑制或治疗剂
WO2018134815A2 (en) * 2017-01-17 2018-07-26 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
KR102771251B1 (ko) 2017-09-08 2025-02-24 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
MX2021001703A (es) 2018-08-13 2021-04-19 Inhibrx Inc Polipeptidos de union a ox40 y sus usos.
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
CN110675421B (zh) * 2019-08-30 2022-03-15 电子科技大学 基于少量标注框的深度图像协同分割方法
US20230233701A1 (en) * 2020-06-02 2023-07-27 Children's Medical Center Corporation Nanobody (vhh) conjugates and uses there of
US20240109954A1 (en) * 2021-02-01 2024-04-04 The General Hospital Corporation Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
US20240117038A1 (en) 2022-07-18 2024-04-11 Ablynx N.V. Cx3cr1-binding compounds, methods and uses thereof
CN120418290A (zh) * 2022-12-22 2025-08-01 凯奥目生物科学株式会社 抗人cx3cr1抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1511850A4 (en) 2002-06-10 2006-06-07 Metabolex Inc METHODS OF TREATING AND DIAGNOSING DIABETES USING MODULATORS OF CX3CR1
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
WO2005103684A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
JP2009504659A (ja) 2005-08-08 2009-02-05 オンコノン・リミテッド・ライアビリティ・カンパニー 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2009147248A2 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010070394A1 (en) 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
EP2486056A1 (en) * 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
JP6076913B2 (ja) * 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
NZ627260A (en) 2012-02-27 2015-10-30 Boehringer Ingelheim Int Cx3cr1-binding polypeptides
EP3035970A1 (en) 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease

Also Published As

Publication number Publication date
CN115925938A (zh) 2023-04-07
US10385134B2 (en) 2019-08-20
EA201400964A1 (ru) 2015-02-27
US11384151B2 (en) 2022-07-12
MD4548C1 (ro) 2018-08-31
TWI598361B (zh) 2017-09-11
US20240026013A2 (en) 2024-01-25
PH12014501912A1 (en) 2014-11-24
ZA202308846B (en) 2025-03-26
IL234018B2 (en) 2023-05-01
JP2015509368A (ja) 2015-03-30
IL291571B1 (en) 2024-04-01
US9783612B2 (en) 2017-10-10
EP4050027A2 (en) 2022-08-31
JP6101715B2 (ja) 2017-03-22
US9458235B2 (en) 2016-10-04
US12221487B2 (en) 2025-02-11
IL234018B1 (en) 2023-01-01
CL2014002072A1 (es) 2015-01-23
CN104245735A (zh) 2014-12-24
PE20141859A1 (es) 2014-12-17
US9035029B2 (en) 2015-05-19
ZA202308845B (en) 2025-03-26
PH12014501912B1 (en) 2023-01-18
TN2014000360A1 (en) 2015-12-21
CN108610421B (zh) 2022-08-19
PH12021553014A1 (en) 2022-09-05
AR090158A1 (es) 2014-10-22
KR20140130685A (ko) 2014-11-11
TW201348256A (zh) 2013-12-01
US20130224224A1 (en) 2013-08-29
GEP201706773B (en) 2017-11-27
US20150239971A1 (en) 2015-08-27
CA2862182A1 (en) 2013-09-06
EP4050027A3 (en) 2022-11-30
IN2014DN05756A (cg-RX-API-DMAC10.html) 2015-04-10
IL311502A (en) 2024-05-01
EA028183B1 (ru) 2017-10-31
US20180030141A1 (en) 2018-02-01
SG11201405283SA (en) 2014-10-30
CN104245735B (zh) 2018-02-23
HK1205154A1 (en) 2015-12-11
AP2014007791A0 (en) 2014-07-31
US20190322753A1 (en) 2019-10-24
EP2820046A1 (en) 2015-01-07
MX349192B (es) 2017-07-18
MD20140104A2 (ro) 2015-02-28
AU2013226340B2 (en) 2017-06-22
ECSP14020402A (es) 2015-11-30
BR112014021080A2 (pt) 2017-07-04
ZA201405021B (en) 2024-09-25
IL234018A0 (en) 2014-09-30
IL291571B2 (en) 2024-08-01
NZ627260A (en) 2015-10-30
IL291571A (en) 2022-05-01
UY34644A (es) 2013-09-02
CN108610421A (zh) 2018-10-02
US20240279349A2 (en) 2024-08-22
MX2014009864A (es) 2014-10-24
US20160355595A1 (en) 2016-12-08
KR102008136B1 (ko) 2019-08-08
WO2013130381A1 (en) 2013-09-06
AU2013226340A1 (en) 2014-07-31
MD4548B1 (ro) 2018-01-31
EP2820046B1 (en) 2022-06-15
US20230046772A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
HK1255604A1 (zh) 抗pd-l1抗体及其用途
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
PE20180499A1 (es) Anticuerpos de union a tau
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
EA201791270A1 (ru) Модифицированные april-связывающие антитела
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
EA202090275A2 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
WO2015026894A3 (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
TN2016000046A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
MX2016009877A (es) Anticuerpos anti-baff novedosos.
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м